The Europe Dementia Treatment Market would witness market growth of 7.0% CAGR during the forecast period (2024-2031).
The Germany market dominated the Europe Dementia Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of$1.88 billion by 2031. The UK market is exhibiting a CAGR of 6.1% during (2024 - 2031). Additionally, The France market would experience a CAGR of 7.8% during (2024 - 2031).
The economic impact of dementia is substantial, affecting not only individuals and families but also healthcare systems and societies at large. The cost of dementia care includes direct medical expenses, such as hospitalizations, medications, and long-term care, as well as indirect costs, such as lost productivity and informal caregiving.
The increasing prevalence of dementia is a primary driver of the growth in the dementia treatment market. In addition, developments in medical research and technology are serving as a driving force behind the market. Continuous research into the underlying mechanisms of dementia has led to the development of innovative therapeutic approaches, including disease-modifying therapies and targeted treatments.
Italy is experiencing significant demographic changes due to its rapidly aging population. The median age of Italy's population is one of the highest in Europe, and the proportion of elderly individuals is anticipated to continue increasing in the subsequent decades. The increasing incidence of dementia in the region has led to a greater emphasis on developing effective treatment strategies and enhancing healthcare infrastructure to manage the growing number of dementia patients. Thus, all the aforementioned elements will support the expansion of the market in the coming years.
Based on Type, the market is segmented into Diagnosis (Imaging Techniques, Cognitive Assessment Tools, Genetic Testing, Biomarker Analysis and Others) and Drugs (Cholinesterase Inhibitors, NMDA Receptor Antagonist, MAO Inhibitors, Combination Drug and Others). Based on Dementia Drugs Route of Administration, the market is segmented into Oral, Transdermal Patch, and Injectable. Based on Dementia Drugs Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on Indication, the market is segmented into Alzheimer’s Disease Dementia, Vascular Dementia, Lewy Body Dementia, Frontotemporal Dementia (FTD), Parkinson Disease Dementia and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The Germany market dominated the Europe Dementia Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of$1.88 billion by 2031. The UK market is exhibiting a CAGR of 6.1% during (2024 - 2031). Additionally, The France market would experience a CAGR of 7.8% during (2024 - 2031).
The economic impact of dementia is substantial, affecting not only individuals and families but also healthcare systems and societies at large. The cost of dementia care includes direct medical expenses, such as hospitalizations, medications, and long-term care, as well as indirect costs, such as lost productivity and informal caregiving.
The increasing prevalence of dementia is a primary driver of the growth in the dementia treatment market. In addition, developments in medical research and technology are serving as a driving force behind the market. Continuous research into the underlying mechanisms of dementia has led to the development of innovative therapeutic approaches, including disease-modifying therapies and targeted treatments.
Italy is experiencing significant demographic changes due to its rapidly aging population. The median age of Italy's population is one of the highest in Europe, and the proportion of elderly individuals is anticipated to continue increasing in the subsequent decades. The increasing incidence of dementia in the region has led to a greater emphasis on developing effective treatment strategies and enhancing healthcare infrastructure to manage the growing number of dementia patients. Thus, all the aforementioned elements will support the expansion of the market in the coming years.
Based on Type, the market is segmented into Diagnosis (Imaging Techniques, Cognitive Assessment Tools, Genetic Testing, Biomarker Analysis and Others) and Drugs (Cholinesterase Inhibitors, NMDA Receptor Antagonist, MAO Inhibitors, Combination Drug and Others). Based on Dementia Drugs Route of Administration, the market is segmented into Oral, Transdermal Patch, and Injectable. Based on Dementia Drugs Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on Indication, the market is segmented into Alzheimer’s Disease Dementia, Vascular Dementia, Lewy Body Dementia, Frontotemporal Dementia (FTD), Parkinson Disease Dementia and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
List of Key Companies Profiled
- Eisai Co., Ltd.
- Eli Lilly And Company
- F.Hoffmann-La Roche Ltd.
- Biogen, Inc.
- AbbVie, Inc.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- GlaxoSmithKline PLC (GSK)
- Cipla Limited
Market Report Segmentation
By Type- Diagnosis
- Imaging Techniques
- Cognitive Assessment Tools
- Genetic Testing
- Biomarker Analysis
- Others
- Drugs
- Cholinesterase Inhibitors
- NMDA Receptor Antagonist
- MAO Inhibitors
- Combination Drug
- Others
- Oral
- Transdermal Patch
- Injectable
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Alzheimer’s Disease Dementia
- Vascular Dementia
- Lewy Body Dementia
- Frontotemporal Dementia (FTD)
- Parkinson Disease Dementia
- Others
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Europe Dementia Treatment Market by Type
Chapter 5. Europe Dementia Treatment Market by Dementia Drugs Route of Administration
Chapter 6. Europe Dementia Treatment Market by Dementia Drugs Distribution Channel
Chapter 7. Europe Dementia Treatment Market by Indication
Chapter 8. Europe Dementia Treatment Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Eisai Co., Ltd.
- Eli Lilly And Company
- F. Hoffmann-La Roche Ltd.
- Biogen, Inc.
- AbbVie, Inc.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- GlaxoSmithKline PLC (GSK)
- Cipla Limited
Methodology
LOADING...
